(TECH) Bio-Techne - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US09073M1045
Stock:
Total Rating 46
Risk 87
Buy Signal -0.24
| Risk 5d forecast | |
|---|---|
| Volatility | 39.4% |
| Relative Tail Risk | -7.08% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.06 |
| Alpha | -24.24 |
| Character TTM | |
|---|---|
| Beta | 1.001 |
| Beta Downside | 1.226 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.32% |
| CAGR/Max DD | -0.18 |
EPS (Earnings per Share)
Revenue
Risks
Fundamental:
P/E ratio: 109.1887
Description: TECH Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 81.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -0.68 > 1.0 |
| NWC/Revenue: 40.89% < 20% (prev 39.58%; Δ 1.31% < -1%) |
| CFO/TA 0.10 > 3% & CFO 249.3m > Net Income 81.1m |
| Net Debt (178.0m) to EBITDA (227.2m): 0.78 < 3 |
| Current Ratio: 4.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (157.0m) vs 12m ago -2.26% < -2% |
| Gross Margin: 65.22% > 18% (prev 0.66%; Δ 6456 % > 0.5%) |
| Asset Turnover: 46.81% > 50% (prev 44.79%; Δ 2.03% > 0%) |
| Interest Coverage Ratio: 13.29 > 6 (EBITDA TTM 227.2m / Interest Expense TTM 9.29m) |
Altman Z'' 5.19
| A: 0.20 (Total Current Assets 637.4m - Total Current Liabilities 140.4m) / Total Assets 2.52b |
| B: 0.44 (Retained Earnings 1.11b / Total Assets 2.52b) |
| C: 0.05 (EBIT TTM 123.5m / Avg Total Assets 2.60b) |
| D: 2.04 (Book Value of Equity 1.05b / Total Liabilities 511.7m) |
| Altman-Z'' Score: 5.19 = AAA |
Beneish M -3.22
| DSRI: 0.83 (Receivables 184.6m/217.9m, Revenue 1.22b/1.20b) |
| GMI: 1.01 (GM 65.22% / 65.62%) |
| AQI: 0.99 (AQ_t 0.63 / AQ_t-1 0.64) |
| SGI: 1.02 (Revenue 1.22b / 1.20b) |
| TATA: -0.07 (NI 81.1m - CFO 249.3m) / TA 2.52b) |
| Beneish M-Score: -3.22 (Cap -4..+1) = AA |
What is the price of TECH shares?
As of March 01, 2026, the stock is trading at USD 59.00 with a total of 1,634,278 shares traded.
Over the past week, the price has changed by +2.57%, over one month by -13.41%, over three months by -8.42% and over the past year by -3.08%.
Over the past week, the price has changed by +2.57%, over one month by -13.41%, over three months by -8.42% and over the past year by -3.08%.
Is TECH a buy, sell or hold?
Bio-Techne has received a consensus analysts rating of 4.13.
Therefore, it is recommended to buy TECH.
- StrongBuy: 7
- Buy: 3
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TECH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 75.3 | 27.5% |
| Analysts Target Price | 75.3 | 27.5% |
TECH Fundamental Data Overview February 27, 2026
P/E Trailing = 109.1887
P/E Forward = 30.3951
P/S = 7.4483
P/B = 5.038
P/EG = 0.8316
Revenue TTM = 1.22b USD
EBIT TTM = 123.5m USD
EBITDA TTM = 227.2m USD
Long Term Debt = 260.0m USD (from longTermDebt, last quarter)
Short Term Debt = 13.7m USD (from shortTermDebt, last quarter)
Debt = 350.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 178.0m USD (from netDebt column, last quarter)
Enterprise Value = 9.23b USD (9.05b + Debt 350.9m - CCE 172.9m)
Interest Coverage Ratio = 13.29 (Ebit TTM 123.5m / Interest Expense TTM 9.29m)
EV/FCF = 41.40x (Enterprise Value 9.23b / FCF TTM 223.0m)
FCF Yield = 2.42% (FCF TTM 223.0m / Enterprise Value 9.23b)
FCF Margin = 18.35% (FCF TTM 223.0m / Revenue TTM 1.22b)
Net Margin = 6.67% (Net Income TTM 81.1m / Revenue TTM 1.22b)
Gross Margin = 65.22% ((Revenue TTM 1.22b - Cost of Revenue TTM 422.8m) / Revenue TTM)
Gross Margin QoQ = 64.65% (prev 65.65%)
Tobins Q-Ratio = 3.66 (Enterprise Value 9.23b / Total Assets 2.52b)
Interest Expense / Debt = 0.62% (Interest Expense 2.17m / Debt 350.9m)
Taxrate = 25.16% (12.8m / 50.8m)
NOPAT = 92.4m (EBIT 123.5m * (1 - 25.16%))
Current Ratio = 4.54 (Total Current Assets 637.4m / Total Current Liabilities 140.4m)
Debt / Equity = 0.17 (Debt 350.9m / totalStockholderEquity, last quarter 2.01b)
Debt / EBITDA = 0.78 (Net Debt 178.0m / EBITDA 227.2m)
Debt / FCF = 0.80 (Net Debt 178.0m / FCF TTM 223.0m)
Total Stockholder Equity = 1.98b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.12% (Net Income 81.1m / Total Assets 2.52b)
RoE = 4.10% (Net Income TTM 81.1m / Total Stockholder Equity 1.98b)
RoCE = 5.52% (EBIT 123.5m / Capital Employed (Equity 1.98b + L.T.Debt 260.0m))
RoIC = 4.04% (NOPAT 92.4m / Invested Capital 2.29b)
WACC = 9.26% (E(9.05b)/V(9.40b) * Re(9.60%) + D(350.9m)/V(9.40b) * Rd(0.62%) * (1-Tc(0.25)))
Discount Rate = 9.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.96%
[DCF] Terminal Value 72.22% ; FCFF base≈235.5m ; Y1≈217.7m ; Y5≈196.8m
[DCF] Fair Price = 16.97 (EV 2.83b - Net Debt 178.0m = Equity 2.65b / Shares 156.5m; r=9.26% [WACC]; 5y FCF grow -9.56% → 2.90% )
EPS Correlation: -23.36 | EPS CAGR: -4.19% | SUE: 1.29 | # QB: 1
Revenue Correlation: 50.42 | Revenue CAGR: 0.50% | SUE: 0.78 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.54 | Chg7d=-0.002 | Chg30d=-0.028 | Revisions Net=-7 | Analysts=12
EPS current Year (2026-06-30): EPS=1.98 | Chg7d=-0.003 | Chg30d=+0.013 | Revisions Net=+2 | Growth EPS=+3.2% | Growth Revenue=+0.5%
EPS next Year (2027-06-30): EPS=2.17 | Chg7d=-0.003 | Chg30d=+0.002 | Revisions Net=+0 | Growth EPS=+9.4% | Growth Revenue=+6.3%
[Analyst] Revisions Ratio: -0.78 (1 Up / 8 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 8.7% (Discount Rate 9.6% - Earnings Yield 0.9%)
[Growth] Growth Spread = -8.8% (Analyst -0.1% - Implied 8.7%)
P/E Forward = 30.3951
P/S = 7.4483
P/B = 5.038
P/EG = 0.8316
Revenue TTM = 1.22b USD
EBIT TTM = 123.5m USD
EBITDA TTM = 227.2m USD
Long Term Debt = 260.0m USD (from longTermDebt, last quarter)
Short Term Debt = 13.7m USD (from shortTermDebt, last quarter)
Debt = 350.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 178.0m USD (from netDebt column, last quarter)
Enterprise Value = 9.23b USD (9.05b + Debt 350.9m - CCE 172.9m)
Interest Coverage Ratio = 13.29 (Ebit TTM 123.5m / Interest Expense TTM 9.29m)
EV/FCF = 41.40x (Enterprise Value 9.23b / FCF TTM 223.0m)
FCF Yield = 2.42% (FCF TTM 223.0m / Enterprise Value 9.23b)
FCF Margin = 18.35% (FCF TTM 223.0m / Revenue TTM 1.22b)
Net Margin = 6.67% (Net Income TTM 81.1m / Revenue TTM 1.22b)
Gross Margin = 65.22% ((Revenue TTM 1.22b - Cost of Revenue TTM 422.8m) / Revenue TTM)
Gross Margin QoQ = 64.65% (prev 65.65%)
Tobins Q-Ratio = 3.66 (Enterprise Value 9.23b / Total Assets 2.52b)
Interest Expense / Debt = 0.62% (Interest Expense 2.17m / Debt 350.9m)
Taxrate = 25.16% (12.8m / 50.8m)
NOPAT = 92.4m (EBIT 123.5m * (1 - 25.16%))
Current Ratio = 4.54 (Total Current Assets 637.4m / Total Current Liabilities 140.4m)
Debt / Equity = 0.17 (Debt 350.9m / totalStockholderEquity, last quarter 2.01b)
Debt / EBITDA = 0.78 (Net Debt 178.0m / EBITDA 227.2m)
Debt / FCF = 0.80 (Net Debt 178.0m / FCF TTM 223.0m)
Total Stockholder Equity = 1.98b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.12% (Net Income 81.1m / Total Assets 2.52b)
RoE = 4.10% (Net Income TTM 81.1m / Total Stockholder Equity 1.98b)
RoCE = 5.52% (EBIT 123.5m / Capital Employed (Equity 1.98b + L.T.Debt 260.0m))
RoIC = 4.04% (NOPAT 92.4m / Invested Capital 2.29b)
WACC = 9.26% (E(9.05b)/V(9.40b) * Re(9.60%) + D(350.9m)/V(9.40b) * Rd(0.62%) * (1-Tc(0.25)))
Discount Rate = 9.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.96%
[DCF] Terminal Value 72.22% ; FCFF base≈235.5m ; Y1≈217.7m ; Y5≈196.8m
[DCF] Fair Price = 16.97 (EV 2.83b - Net Debt 178.0m = Equity 2.65b / Shares 156.5m; r=9.26% [WACC]; 5y FCF grow -9.56% → 2.90% )
EPS Correlation: -23.36 | EPS CAGR: -4.19% | SUE: 1.29 | # QB: 1
Revenue Correlation: 50.42 | Revenue CAGR: 0.50% | SUE: 0.78 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.54 | Chg7d=-0.002 | Chg30d=-0.028 | Revisions Net=-7 | Analysts=12
EPS current Year (2026-06-30): EPS=1.98 | Chg7d=-0.003 | Chg30d=+0.013 | Revisions Net=+2 | Growth EPS=+3.2% | Growth Revenue=+0.5%
EPS next Year (2027-06-30): EPS=2.17 | Chg7d=-0.003 | Chg30d=+0.002 | Revisions Net=+0 | Growth EPS=+9.4% | Growth Revenue=+6.3%
[Analyst] Revisions Ratio: -0.78 (1 Up / 8 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 8.7% (Discount Rate 9.6% - Earnings Yield 0.9%)
[Growth] Growth Spread = -8.8% (Analyst -0.1% - Implied 8.7%)